Hemab Therapeutics Holdings, Inc. Common Stock
NASDAQ:COAGBiotechnology
+$2.32 today
- Market cap
- $1.83B
- Beta
- 0.00
Volume 0.30M
Average 0.34M
COAG Operating Cash Flow
Cash generated by the company's core business operations during the period.
Hemab Therapeutics Holdings, Inc. Common StockNASDAQ: COAG
Operating Cash Flow · Q2 FY2026 · quarter ended Jun 2026
Operating cash flow of -$22.64M in Q2 FY2026
Q2 FY2026 operating cash flow was -$22.64M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Operating Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (61.48M) USD
- Year-over-year change
- —
| Period | Period end | Operating Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (61.48M) | — |
Operating Cash Flow vs competitors
How COAG compares with its peers on the latest reported figures
- COAG's FY2025 operating cash flow of $61.48M is the 3rd largest of the 5 companies compared; the peer median is $101.03M.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
IRONDisc Medicine, Inc. | LTM Sep 2026 | $189.94M | +15.3% | +62.2% | — |
| LTM Mar 2026 | $172.11M | +3.5% | +7.1% | 951.2% | |
COAGHemab Therapeutics Holdings, Inc. Common Stock | FY2025 | $61.48M | — | — | — |
DMRADamora Therapeutics, Inc. | LTM Jun 2024 | $29.96M | — | -46.1% | — |
| LTM Mar 2026 | $27.59M | -37.3% | -19.6% | 3215.2% | |
| Peer median (excluding COAG) | $101.03M | +3.5% | -6.3% | 2083.2% | |
Competitors are the stored peer set for COAG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2025 Dec 2025 |
|---|---|
| Net Income | (63.91M) |
| Depreciation & Amortization | 304K |
| Deferred Income Tax | 0 |
| Stock-Based Compensation | 2.01M |
| Change in Working Capital | 1.36M |
| Accounts Receivables | 0 |
| Inventory | 0 |
| Accounts Payables | 2.58M |
| Other Working Capital | (1.22M) |
| Other Non-Cash Items | (1.23M) |
| Operating Cash Flow | (61.48M) |
| Capital Expenditures | (16K) |
| Acquisitions (Net) | 0 |
| Purchases of Investments | (252.5M) |
| Sales of Investments | 171.03M |
| Other Investing Activities | 0 |
| Investing Cash Flow | (81.48M) |
| Debt Repayment | (120K) |
| Common Stock Issued | 0 |
| Common Stock Repurchased | 0 |
| Dividends Paid | 0 |
| Other Financing Activities | 0 |
| Financing Cash Flow | 156.3M |
| Effect of Forex Changes | 223K |
| Net Change in Cash | 13.57M |
| Free Cash Flow | (61.49M) |
Hemab Therapeutics Holdings, Inc. Common Stock
NASDAQ:COAG
Intrinsic Alpha fair value
Locked
Current Price
$39.15
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.